MOLN Molecular Partners

Life Science Cares Launches in Switzerland

Life Science Cares Launches in Switzerland

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States.

“We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel,” said Nadine Zahnd, Managing Director of LSCS. “At the heart of our life sciences community is the overwhelming sense to act and do good. We are building bridges between Swiss Life Science Organizations and local charitable organizations for individuals who may otherwise fail to access the opportunities afforded to so many of us.”

In Switzerland in 2021, 1.24 million people, including many families are considered at the brink of poverty. Those affected are at risk of losing their social contacts and often suffer from psychological and physical health problems. Children in such families face often insurmountable obstacle to reach their full potential. It is the mission of LSCS to break this cycle and offer a path to unlock opportunity.

At the Swiss Biotech Day, LSCS will be showcased in the Plenary Session on 22 April 2024 and in a dedicated Panel discussion featuring the Swiss Red Cross, Cooley LLP, Novartis, the Swiss Biotech Association (SBA) and Molecular Partners at 4.30 pm at Marriott Hotel in Basel. Information will be available for everyone who wishes to contribute to our mission at the SBA Booth.

The Board of LSCS will be constituted by Isabel Dalli, Novartis; Sarah MacDonald, CEO LSC, Inc.; Dorothea Bergler, Swiss Red Cross; Patrick Amstutz, Swiss Biotech Association / Molecular Partners; Dieter Gericke, Homburger; Christoph Schmidt, up&up communication.

Founding Members include Ulf Grawunder, Founder and former CEO of NBE Therapeutics; Bill Burns, former CEO of Roche Pharmaceuticals; Dominik Höchli, former Head of Global Medical Affairs at Abbvie; Patrick Amstutz, CEO of Molecular Partners and Chairman of Swiss Biotech Association, as well as Molecular Partners, OM Pharma, the Swiss Biotech Association, HBM Healthcare Investments and others.

About Life Science Cares Switzerland:

Life Science Cares Switzerland brings together the life science community and local non-profit organizations to build bridges for people with limited opportunities in our country. Our goal is to provide access to education and opportunity for all who wish to develop beyond their own limitations – by connecting the talents and minds of the life science community with the hearts of non-profit organizations. Learn more at

Contact:

Life Science Cares Switzerland

Nadine Zahnd-Straumann

Scheuchzerstrasse 35

CH-8006 Zürich



EN
19/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE

Molecular Partners Announces Publication in Cancer Immunology Research...

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action  Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in...

 PRESS RELEASE

Life Science Cares Launches in Switzerland

Life Science Cares Launches in Switzerland First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States. “We are excited to launch Life Sci...

 PRESS RELEASE

Molecular Partners Announces All Board Proposals Approved at the Annua...

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated fina...

Molecular Partners AG: 1 director

A director at Molecular Partners AG sold 60,000 shares at 4.050CHF and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Molecular Partners Publishes Invitation to Annual General Meeting 2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024. The Annual General Meeting will be held on Wednesday, April 17, 2024, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. to the Annual General Meeting 2024 with the correspon...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch